Accessing complex therapies often involves a maze of specialty pharmacies, third-party administrators, insurance hurdles and extensive paperwork. Each touchpoint can become a point of failure, which contributes to prescription abandonment that nears one in ten overall and rises to 60% when out-of-pocket costs exceed €460. As expectations for timely, coordinated support increase, pharmaceutical companies are moving to regain visibility and control over patient interactions. Mature technologies now enable compliant, real-time insight into where patients encounter friction, offering a route to intervene before engagement is lost and to redesign support around needs rather than processes. This shift is reshaping the traditional hub model and raising the bar for data governance, vendor transparency and the balance between automation and human care.
From Outsourced Hubs to Hybrid Control
Hubs emerged to scale patient services across fragmented systems, handling access, benefits checks and enrolment in financial assistance. Over time, manual workflows and siloed systems left oversight dependent on retrospective performance reviews, which often arrive after the opportunity to correct course has passed. The consequences include delayed starts, drop-off during enrolment and frustration for patients and prescribers, alongside reputational and revenue impacts for manufacturers. The model is now changing as companies seek more direct accountability for experience and outcomes.
Advanced AI and automation can deliver compliant redaction of personally identifiable information at scale. This allows analysis of patient conversations and call-centre interactions without compromising privacy, turning a black-box service into a stream of actionable signals that can be monitored continuously. Some manufacturers are insourcing the technology stack, including telephony and call recording, while continuing to outsource staffing. A hybrid hub that keeps data and core platforms in-house can generate consistent visibility into sentiment, compliance and service quality, while enabling rapid response to market events such as safety alerts. Transactional tasks like benefits verification can be automated, while sensitive interactions remain the domain of trained professionals who provide context, judgement and reassurance.
Compliant Visibility and Vendor Accountability
Greater ownership of data requires new expectations for hub partners. Traditional outsourced models tend to provide quarterly summaries and surface-level quality metrics, with little transparency into the underlying interactions. With compliant analytics now available, manufacturers can set standards for real-time access to conversation data, experience trends and operational signals that indicate when and where patients are getting stuck. This shift depends on clear ownership agreements, negotiated data-sharing requirements and shared accountability across the ecosystem, so that insights flow back to the teams who can act on them.
Must Read: Barriers to Medical Care in the EU
Real-time visibility changes the tempo of support. AI can flag dropped calls, bottlenecks in enrolment and patterns that predict disengagement. However, detection alone is insufficient. Turning insight into action requires retraining partners, reengineering workflows and redefining success measures to reflect what matters to patients rather than what is easiest to capture or monetise. That may mean redesigning intake steps, changing escalation thresholds or shifting capacity to match demand at known friction points. The objective is to close the loop between monitoring and intervention so that fewer patients abandon therapy due to avoidable administrative barriers.
Governance, Human Oversight and Sustainable Change
As adoption accelerates, governance must keep pace. Without clear standards for compliance, bias mitigation and safety, promising tools can become liabilities in a privacy-sensitive environment. Manufacturers are establishing formal governance committees to evaluate training data, define performance thresholds and codify human-in-the-loop processes. Key considerations include who trained a model, how performance will be monitored for drift and bias, and what level of human oversight is required at each step. Strong governance provides the framework to deploy automation where it adds value and to maintain human control where stakes and sensitivity are highest.
Balancing automation with empathy is essential. Certain touchpoints are repeatable and suitable for automation, such as verifying benefits or configuring copay support. Others demand human judgement and emotional intelligence, for example guiding a patient through a serious diagnosis or concerns about side effects. Strategies that blend both can reduce administrative friction without sacrificing the relationship-centred support that sustains adherence. Manufacturers that plan for this balance from the outset can use AI to handle volume and variability while preserving human quality at moments that define trust.
Sustained progress will depend on long-term investment rather than quick fixes. Owning the data and governing the tech stack enables consistent measurement and continuous improvement across hub operations. It also supports a more durable operating model that aligns vendor performance with patient outcomes. With the tools now available to observe and improve the journey in real time, the imperative is to build the capabilities and partnerships that translate signals into better access, fewer abandoned prescriptions and stronger continuity of care.
Manufacturers are moving beyond retrospective hub oversight toward a model that integrates compliant analytics, clear data ownership and a deliberate balance of automation and human support. By insourcing core technology, demanding real-time transparency from partners and strengthening governance, teams can act earlier to remove friction and keep patients on therapy. The opportunity is to turn visibility into reliable operational change so that access pathways are simpler, support is timely, and patient experience is consistently managed across the journey. With infrastructure and insight now within reach, the next phase rests on disciplined execution that aligns process, technology and people around patient needs.
Source: MedCity News
Image Credit: iStock
